The Precision Peptide Company Applauds FDA Action Advancing Regulatory Clarity for Peptide Therapies

Recent Developments

• On April 16, 2026, the company announced that the U.S. Food and Drug Administration (FDA) has moved several peptides from Category 2 of bulk drug substances to independent expert review by the Pharmacy Compounding Advisory Committee (PCAC).
• This regulatory shift aims to establish a transparent, science-driven framework for peptide therapies.
• The company granted 800,000 stock options to consultants at an exercise price of $0.50 per share with terms ranging from one to three years.
• On April 15, 2026, the company entered into service agreements: Think Ink Marketing Data ($250,000 budget) and Ouimet Consulting Inc. ($65,000 fee).

Regulatory Clarity Impact

• The FDA action is positive for the sector but does not guarantee immediate commercialization of specific products for Precision Peptide.
• Moving from Category 2 to PCAC review implies increased scrutiny rather than immediate deregulation, though it provides a clearer pathway for compliance.
• CEO quotes suggest this benefits investors by separating credible innovation from unregulated markets, which supports long-term valuation but lacks short-term revenue catalysts.

Business Model

• The company focuses on peptide therapies, navigating regulatory frameworks for bulk drug substances in the U.S. market.
• Flagship initiative involves securing regulatory clarity to enable safe access to peptides for customers and patients.
• Recent focus includes public relations and business development through third-party consultants.